ArticleTherapeutics and clinical risk management2008
New advances in the treatment of Clostridium difficile infection (CDI).
Article in Therapeutics and clinical risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Reducing Clostridium difficile in the Inpatient Setting: A Systematic Review of the Adherence to and Effectiveness of C. difficile Prevention Bundles.Infection control and hospital epidemiology · 2017Pooled it
- The Bile Acid-Diet-Microbiome Axis inNutrients · 2026Review
- Synthesis of PSI Oligosaccharide for the Development of Total Synthetic Vaccine againstThe Journal of organic chemistry · 2025Article
- Biofilm Formation ofMicroorganisms · 2023Review
- Mucosal Vaccination Strategies againstVaccines · 2023Review
- Peroxisome proliferator-activated receptor-γ as the gatekeeper of tight junction inFrontiers in microbiology · 2022Article
- Clostridioides difficile phage biology and application.FEMS microbiology reviews · 2021Review
- Prevalence and antimicrobial susceptibility pattern of toxigenic Clostridium difficilestrains isolated in IranTurkish journal of medical sciences · 2019Article
- Treatment withTherapeutics and clinical risk management · 2019Article
- Characterization of Bacteriophages Infecting Clinical Isolates ofFrontiers in microbiology · 2018Article
- Effect ofFrontiers in microbiology · 2018Article
- Nonantimicrobial drug targets for Clostridium difficile infections.Future microbiology · 2017Article
- Review
- Octahedron Iron Oxide Nanocrystals Prohibited Clostridium difficile Spore Germination and Attenuated Local and Systemic Inflammation.Scientific reports · 2017Article
- Management ofGastroenterology & hepatology · 2016Article
- Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.The Journal of antimicrobial chemotherapy · 2016Article
- Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI.Open forum infectious diseases · 2016Article
- Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.Antimicrobial agents and chemotherapy · 2015Article
- Association of tcdA+/tcdB+ Clostridium difficile Genotype with Emergence of Multidrug-Resistant Strains Conferring Metronidazole Resistant Phenotype.Iranian biomedical journal · 2015Article
- Synthetic polymers active against Clostridium difficile vegetative cell growth and spore outgrowth.Journal of the American Chemical Society · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile infections (CDI) have increased in frequency throughout the world. In addition to an increase in frequency, recent CDI epidemics have been linked to a hypervirulent C. difficile strain resulting in greater severity of disease. Although most mild to moderate cases of CDI continue to respond to metronidazole or vancomycin, refractory and recurrent cases of CDI may require alternative therapies. This review provides a brief overview of CDI and summarizes studies involving alternative antibiotics, toxin binders, probiotics, and immunological therapies that can be considered for treatment of acute and recurrent CDI in severe and refractory situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.